세계의 섬유근육통 치료 시장 규모 : 약제 클래스별, 치료별, 최종 사용자별, 지역 범위별 예측

Global Fibromyalgia Treatment Market Size By Drug Class, By Treatment, By End-Users, By Geographic Scope And Forecast

US $ 3,950 ￦ 5,411,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 4,850 ￦ 6,644,000

PDF & Excel (5 User License)

PDF 및 Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 7,550 ￦ 10,344,000

PDF & Excel (Enterprise User License)

PDF 및 Excel 보고서를 동일기업내 모든 분들이 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

한글목차

섬유근육통 치료 시장 규모와 예측

섬유근육통 치료 시장 규모는 2024년에 18억 1,176만 달러로 평가되었고 2026-2032년에 걸쳐 4.15%의 연평균 복합 성장률(CAGR)을 나타내 2032년에는 25억 828만 달러에 달할 것으로 예측됩니다.

• 섬유근육통 치료란 광범위한 근골격계의 통증, 피로, 인지장애를 특징으로 하는 만성질환인 섬유근육통의 증상을 관리하기 위해 고안된 일련의 의료요법, 약제요법, 기타 해결책을 말합니다.
• 이것은 주로, 병원, 클리닉, 약국 등의 의료 제공자가, 섬유근육통에 시달리는 환자를 치료하기 위해서 이용하고 있습니다
• 섬유근육통의 관리에는 통증 완화제, 항우울제, 항경련제 등의 통증 관리, 물리치료, 상담 등이 일반적으로 사용됩니다.
• 섬유근육통의 증상을 완화하고, 통증을 경감하고, 수면장애나 우울증 등의 관련 질환을 관리하는 것으로, 섬유근육통 환자의 생활의 질을 향상시키기 위해서 이용됩니다.
• 섬유근육통에 대한 이해가 깊어짐에 따라, 이 만성적이고 종종 쇠약해지는 증상으로부터의 해방을 요구하는 환자수 증가에 대응해, 새로운 치료 선택지를 제공하는 것으로 시장은 확대하고 있습니다.
• 섬유근육통은 전신의 통증, 피로, 수면, 기억, 기분 장애를 일으키는 장기적인 질환입니다.
• 섬유근육통은 만성적인 질환이며, 다양한 증상을 동반하기 때문에 치료는 질병을 치료하는 것보다는 증상을 관리하는 것에 주안이 놓여져 있습니다.

세계의 섬유근육통 치료 시장 역학

세계의 섬유근육통 치료 시장을 형성하는 주요 시장 역학은 다음과 같습니다.

주요 시장 성장 촉진요인

• 섬유근육통의 유병률 증가 : 세계적으로 섬유근육통으로 진단되는 환자수가 증가하고 있어 효과적인 치료 옵션에 대한 수요가 높아지고 있습니다.
• 질병에 대한 인식 증가 : 인지도 향상 및 진단 방법 개선으로 치료를 원하는 환자가 증가하고 있습니다.
• 의약품 개발 진보 : 미국 국립보건실(NIH)의 보고에 따르면 섬유근육통 연구를 위한 자금은 2019년 1,300만 달러에서 2023년에는 1,800만 달러로 38% 증가했습니다. FDA에 따르면 현재 섬유근육통 치료에 특화된 임상검사가 25개 이상 있으며 다양한 단계에 있습니다. 제약회사는 섬유근육통에 대한 보다 효과적인 신약 개발에 주력하고 있으며 시장 성장을 이끌고 있습니다.
• 헬스케어 인프라 개선 : 특히 개발도상지역에서 의료시설의 개발로 섬유근육통 치료에 대한 접근이 증가하고 있습니다.
• 비의약품 요법에 대한 수요 증가 : 인지 행동 치료(CBT) 및 신체 재활과 같은 대체 요법에 대한 선호도 증가가 시장 성장을 뒷받침하고 있습니다.

주요 시장 과제

• 진단의 어려움 : 섬유근육통은 다른 질병과 증상이 중복되기 때문에 진단이 어렵고 시기 적절한 치료를 방해합니다.
• 개발 도상 지역의 낮은 인지도 : 특정 지역의 인지도 및 진단 도구의 부족은 시장 잠재력을 제한합니다.
• 기존 약물의 부작용 : 많은 섬유근육통 치료에는 심각한 부작용이 있으며 환자의 복용 충동과 시장 성장에 영향을 미칩니다.
• 높은 치료 비용 : 특히 저소득층에서는 약물 및 치료 비용이 접근을 제한할 수 있습니다.
• 치료법 부족 : 영구적인 치료법이 없기 때문에 시장은 대증 요법으로 제한되며 장기적인 효과는 제한적입니다.

주요 시장 동향

• 개인화 의학 개발 : 개인화 치료에 대한 관심이 높아지고 섬유근육통 시장의 견인 역할이되었습니다.
• 원격 의료 통합 : 원격 의료 플랫폼이 널리 보급되어 환자는 진찰과 후속 조치를 받기 쉽습니다.
• 비의약품 치료의 성장 : 마인드플루네스, 침술, 운동 프로그램 등의 대체 요법을 선택하는 환자가 증가하고 있습니다.
• 병용요법 : 보다 종합적인 치료를 위해 의약품과 비의약품 치료를 조합하는 경향이 강해지고 있습니다.
• 생물제제의 조사 : 섬유근육통의 증상의 근본적인 원인을 대상으로 한 생물제제나 신규 요법에 관한 새로운 연구가 행해지고 있어, 장래에는 보다 효과적인 해결책이 기대되고 있습니다.

목차

제1장 서론

• 시장 정의
• 시장 세분화
• 조사 스케줄
• 전제조건
• 한계

제2장 조사 방법

• 데이터 마이닝
• 2차 조사
• 1차 조사
• 전문가의 조언
• 퀄리티 체크
• 최종 리뷰
• 데이터의 삼각측량
• 상향식 접근
• 하향식 접근
• 조사의 흐름
• 데이터 소스

제3장 주요 요약

• 세계의 섬유근육통 치료 시장 개요
• 세계의 섬유근육통 치료 생태 매핑
• 세계의 섬유근육통 치료 절대적 수익 기회
• 세계의 섬유근육통 치료 시장 매력(지역별)
• 세계의 섬유근육통 치료 시장 : 지역별
• 세계의 섬유근육통 치료 시장 : 유통 채널별
• 세계의 섬유근육통 치료 시장 : 약제 클래스별
• 향후 시장 기회
• 세계 시장 내역

제4장 시장 전망

• 세계의 섬유근육통 치료 시장 전망
• 시장의 진화
• 시장 성장 촉진요인
  • 신규 섬유근육통 치료의 승인과 출시
  • 강력한 제품 파이프라인과 섬유근육통 증가
• 성장 억제요인
  • 섬유근육통 치료의 부작용
  • 적응 외약이나 제네릭 의약품의 채용 증가
• 가능성
  • 섬유근육통 치료를 위한 새로운 치료법 개발을 위한 연구개발 활동 증가
• 세계의 섬유근육통 치료 시장에 미치는 COVID-19의 영향
• 거시경제 분석
• Porter's Five Forces 분석
  • 신규 참가업체의 위협
  • 대체품의 위협
  • 공급기업의 협상력
  • 구매자의 협상력
  • 경쟁 기업간 경쟁 관계
• 가격 분석

제5장 약제 클래스별 시장

• 개요
• 항우울제
• 항경련제
• 진통제
• 근육 이완제

제6장 치료별 시장

• 개요
• 약물 치료
• 치료
• 라이프 스타일의 변화

제7장 최종 사용자별 시장

• 개요
• 병원
• 클리닉

제8장 지역별 시장

• 개요
• 북미
  • 북미 시장 현황
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽 시장 현황
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 아시아태평양 시장 현황
  • 중국
  • 인도
  • 일본
  • 기타 아시아태평양
• 라틴아메리카
  • 라틴아메리카 시장 현황
  • 브라질
  • 아르헨티나
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 중동 및 아프리카 시장 현황
  • 아랍에미리트(UAE)
  • 사우디아라비아
  • 남아프리카
  • 기타 중동 및 아프리카

제9장 경쟁 구도

• 개요
• 기업 시장 랭킹 분석
• 지역별 실적
• 기업의 산업별 실적
• 에이스 매트릭스
  • 액티브
  • 최첨단
  • 에머징
  • 이노베이터

제10장 기업 프로파일

• PFIZER
• INNOVATIVE MED CONCEPTS
• NOVARTIS AG
• ELI LILLY & COMPANY
• SUN PHARMACEUTICAL INDUSTRIES LTD.
• INTEC PHARMA LTD.
• ABBVIE
• FSD PHARMA
• MERCK & CO.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.

KTH

영문 목차

영문목차

Fibromyalgia Treatment Market Size And Forecast

Fibromyalgia Treatment Market size was valued at USD 1811.76 Million in 2024 and is projected to reach USD 2508.28 Million by 2032, growing at a CAGR of 4.15% from 2026 to 2032.

• Fibromyalgia treatment refers to the range of medical therapies, medications, and other solutions designed to manage the symptoms of fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties.
• This is primarily utilized by healthcare providers, including hospitals, clinics, and pharmacies, to treat patients suffering from fibromyalgia.
• Medications like pain relievers, antidepressants, and anti-seizure drugs, as well as physical therapy and counseling, are commonly used in fibromyalgia management.
• It is used to improve the quality of life for fibromyalgia patients by alleviating symptoms, reducing pain, and managing associated conditions such as sleep disturbances and depression.
• As the understanding of fibromyalgia improves, the market is expanding with new treatment options, catering to the growing number of patients seeking relief from this chronic, often debilitating condition.
• Fibromyalgia is a long-term disorder that causes pain throughout the body, fatigue, and difficulties with sleep, memory, and mood.
• Due to the chronic nature of the condition and the variety of symptoms associated with it, treatment is primarily focused on managing the symptoms rather than curing the disease.

Global Fibromyalgia Treatment Market Dynamics

The key market dynamics that are shaping the global fibromyalgia treatment market include:

Key Market Drivers

• Increasing Prevalence of Fibromyalgia: The rising number of people diagnosed with fibromyalgia globally is driving demand for effective treatment options.
• Growing Awareness of the Disorder: Enhanced public awareness and better diagnostic methods are leading to more individuals seeking treatment.
• Advancements in Drug Development: The National Institutes of Health (NIH) reported funding for fibromyalgia research increased from $13 million in 2019 to $18 million in 2023, a 38% increase. According to the FDA, there are currently over 25 clinical trials specifically focused on fibromyalgia treatments in various phases. Pharmaceutical companies are focusing on the development of new and more effective drugs for fibromyalgia, driving market growth.
• Improved Healthcare Infrastructure: Expanding healthcare facilities, especially in developing regions, is increasing access to fibromyalgia treatments.
• Rising Demand for Non-Pharmaceutical Therapies: The growing preference for alternative therapies like cognitive behavioral therapy (CBT) and physical rehabilitation is boosting market growth.

Key Market Challenges:

• Difficulty in Diagnosis: Fibromyalgia can be difficult to diagnose due to overlapping symptoms with other conditions, hindering timely treatment.
• Limited Awareness in Developing Regions: Lack of awareness and diagnostic tools in certain regions limits the market potential.
• Side Effects of Existing Medications: Many fibromyalgia drugs have significant side effects, affecting patient adherence and market growth.
• High Treatment Costs: The expense of medications and therapies can limit access, particularly in low-income areas.
• Lack of Curative Treatment: The absence of a permanent cure restricts the market to symptom management, limiting long-term effectiveness.

Key Market Trends:

• Development of Personalized Medicine: The increasing focus on personalized treatment approaches is gaining traction in the fibromyalgia market.
• Integration of Telemedicine: Telemedicine platforms are becoming more prevalent, allowing patients easier access to consultations and follow-ups.
• Non-Pharmaceutical Treatment Growth: More patients are opting for alternative therapies such as mindfulness, acupuncture, and exercise programs.
• Combination Therapies: There is a growing trend toward combining pharmaceutical and non-pharmaceutical treatments for more comprehensive care.
• Research in Biologics: New research is being conducted into biologics and novel therapies that target the root causes of fibromyalgia symptoms, promising more effective solutions in the future.

Global Fibromyalgia Treatment Market Regional Analysis

Here is a more detailed regional analysis of the fibromyalgia treatment market:

North America

• The North American region significantly dominates the Global Fibromyalgia Treatment Market owing to the rising prevalence of fibromyalgia and a well-established healthcare infrastructure.
• According to the Centers for Disease Control and Prevention (CDC), fibromyalgia affects about 4 million US adults, approximately 2% of the adult population.
• The National Fibromyalgia Association reports that the condition is more prevalent in women, with females accounting for 75-90% of cases.
• The U.S. leads the market, driven by increased diagnosis rates, greater public awareness of the condition, and the availability of advanced treatment options.
• The presence of key pharmaceutical companies focused on developing innovative therapies for fibromyalgia further strengthens the region's market position.
• Growing research and development activities aimed at discovering new drugs and treatment modalities have fueled market expansion.
• Government initiatives and healthcare programs in the U.S. and Canada to promote awareness and provide access to treatment for chronic pain conditions have played a crucial role in market growth.
• The rising demand for personalized medicine and alternative therapies such as cognitive behavioral therapy (CBT), physiotherapy, and mindfulness practices is also influencing the market dynamics in North America.
• The high cost of treatment and the side effects associated with some medications remain key challenges in the region.
• Despite this, North America's dominant healthcare infrastructure and ongoing advancements in fibromyalgia treatment continue to drive market growth.

Asia Pacific

• The Asia Pacific region is anticipated to witness the fastest growth in the Global Fibromyalgia Treatment Market, driven by increasing awareness of chronic pain conditions and improving healthcare infrastructure.
• Countries such as China, Japan, India, and South Korea are contributing to market expansion as healthcare access becomes more widespread and diagnosis rates for fibromyalgia improve.
• The region's growing aging population is also a key factor, as fibromyalgia tends to affect older adults more frequently.
• Rising healthcare expenditure and the availability of affordable treatment options are facilitating the market's growth in Asia Pacific.
• Governments in countries like India and China are initiating healthcare reforms aimed at increasing the accessibility of pain management therapies, which is positively impacting the fibromyalgia treatment market.
• Despite these advancements, challenges such as low awareness in rural areas and limited availability of specialized treatment centers pose obstacles to market growth.
• The increasing focus on research and development, along with the growing demand for non-invasive treatments and alternative therapies like acupuncture and herbal medicines, is expected to drive continued growth in the Asia Pacific fibromyalgia treatment market in the coming years.

Global Fibromyalgia Treatment Market: Segmentation Analysis

The Global Fibromyalgia Treatment Market is segmented based on Drug Class, Treatment, End-Users, and Geography.

Fibromyalgia Treatment Market, By Drug Class

• Antidepressants
• Anticonvulsants
• Analgesics
• Muscle Relaxants

Based on drug class, the Global Fibromyalgia Treatment Market is segmented into Antidepressants, Anticonvulsants, Analgesics, and Muscle Relaxants. The Antidepressant segment significantly dominates the Global Fibromyalgia Treatment Market owing to their effectiveness in reducing pain and improving mood in fibromyalgia patients.

Fibromyalgia Treatment Market, By Treatment

• Medication
• Therapy
• Lifestyle Changes

Based on treatment, the Global Fibromyalgia Treatment Market is segmented into Medication, Therapy, and Lifestyle Changes. The Medication segment significantly dominates the Global Fibromyalgia Treatment Market owing to its central role in symptom management, with drugs like antidepressants and pain relievers commonly prescribed.

Fibromyalgia Treatment Market, By End-Users

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies

Based on end-users, the Global Fibromyalgia Treatment Market is segmented into Hospitals, Clinics, Retail Pharmacies, and Online Pharmacies. Hospitals significantly dominate the Global Fibromyalgia Treatment Market owing to the availability of specialized care and advanced treatment options for fibromyalgia patients.

Fibromyalgia Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the global fibromyalgia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region significantly dominates the Global Fibromyalgia Treatment Market owing to the rising prevalence of fibromyalgia and a well-established healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC), fibromyalgia affects about 4 million US adults, approximately 2% of the adult population. The National Fibromyalgia Association reports that the condition is more prevalent in women, with females accounting for 75-90% of cases. The U.S. leads the market, driven by increased diagnosis rates, greater public awareness of the condition, and the availability of advanced treatment options.

Key Players

The "Global Fibromyalgia Treatment Market" study report provides valuable insight with an emphasis on the global market. The major players in the market are Fizer, Innovative Med Concepts, Novartis AG, Eli Lilly & Company, Sun Pharmaceutical Industries Ltd., Intec Pharma Ltd., AbbVie, FSD Pharma, Merck & Co., Teva Pharmaceutical Industries Ltd., Lupin Limited, Viatris Inc., Tonix Pharmaceuticals Holding Corp., and Aptinyx Inc.

• This section offers in-depth analysis through a company overview, position analysis, the regional and industrial footprint of the company, and the ACE matrix for insightful competitive analysis. The section also provides an exhaustive analysis of the financial performances of mentioned players in the given market.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Fibromyalgia Treatment Market Key Developments

• In August 2022, Aptinyx Inc. announced the results from a Phase 2b clinical study that evaluated the effects of NYX-2925 in patients with fibromyalgia. The study revealed that NYX-2925 did not achieve statistically significant separation from placebo on the primary endpoint, which measured the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12.
• In October 2020, Eli Lily announced a collaboration with Daiichi Sankyo in Japan for the commercialization of Galcanezumab, an anti-CGRP antibody potentially used to treat migraines. Under this agreement, Daiichi Sankyo was responsible for the sales and distribution of Galcanezumab, while Eli Lily Japan retained the marketing license, pending marketing approval.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL FIBROMYALGIA TREATMENT MARKET OVERVIEW
• 3.2 GLOBAL FIBROMYALGIA TREATMENT ECOLOGY MAPPING
• 3.3 GLOBAL FIBROMYALGIA TREATMENT ABSOLUTE MARKET OPPORTUNITY
• 3.4 GLOBAL FIBROMYALGIA TREATMENT MARKET ATTRACTIVENESS, BY REGION
• 3.5 GLOBAL FIBROMYALGIA TREATMENT MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.6 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (USD MILLION)
• 3.7 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS (USD MILLION)
• 3.8 FUTURE MARKET OPPORTUNITIES
• 3.9 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

• 4.1 GLOBAL FIBROMYALGIA TREATMENT MARKET OUTLOOK
• 4.2 MARKET EVOLUTION
• 4.3 MARKET DRIVERS
  • 4.3.1 APPROVAL AND LAUNCH OF NOVEL FIBROMYALGIA TREATMENT DRUGS
  • 4.3.2 STRONG PRODUCT PIPELINE AND INCREASING OCCURRENCE OF FIBROMYALGIA
• 4.4 RESTRAINTS
  • 4.4.1 SIDE EFFECTS OF THE DRUGS USED FOR THE TREATMENT OF FIBROMYALGIA
  • 4.4.2 HIGHER ADOPTION OF OFF-LABEL AND GENERIC DRUGS
• 4.5 OPPORTUNITIES
  • 4.5.1 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR THE DEVELOPMENT OF NEW THERAPIES FOR THE TREATMENT OF FIBROMYALGIA
• 4.6 IMPACT OF COVID19 ON GLOBAL FIBROMYALGIA TREATMENT MARKET
• 4.7 MACROECONOMIC ANALYSIS
• 4.8 PORTER'S FIVE FORCES ANALYSIS
  • 4.8.1 THREAT OF NEW ENTRANTS
  • 4.8.2 THREAT OF SUBSTITUTES
  • 4.8.3 BARGAINING POWER OF SUPPLIERS
  • 4.8.4 BARGAINING POWER OF BUYERS
  • 4.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 4.9 PRICING ANALYSIS

5 MARKET, BY DRUG CLASS

• 5.1 OVERVIEW
• 5.2 ANTIDEPRESSANTS
• 5.3 ANTICONVULSANTS
• 5.4 ANALGESICS
• 5.5 MUSCLE RELAXANTS

6 MARKET, BY TREATMENT

• 6.1 OVERVIEW
• 6.2 MEDICATION
• 6.3 THERAPY
• 6.4 LIFESTYLE CHANGES

7 MARKET, BY END-USERS

• 7.1 OVERVIEW
• 7.2 HOSPITALS
• 7.2 CLINICS

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 NORTH AMERICA MARKET SNAPSHOT
  • 8.2.2 U.S.
  • 8.2.3 CANADA
  • 8.2.4 MEXICO
• 8.3 EUROPE
  • 8.3.1 EUROPE MARKET SNAPSHOT
  • 8.3.2 GERMANY
  • 8.3.3 U.K.
  • 8.3.4 FRANCE
  • 8.3.5 ITALY
  • 8.3.6 SPAIN
  • 8.3.7 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 ASIA PACIFIC MARKET SNAPSHOT
  • 8.4.2 CHINA
  • 8.4.3 INDIA
  • 8.4.4 JAPAN
  • 8.4.5 REST OF ASIA PACIFIC
• 8.5 LATIN AMERICA
  • 8.5.1 LATIN AMERICA MARKET SNAPSHOT
  • 8.5.2 BRAZIL
  • 8.5.3 ARGENTINA
  • 8.5.4 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
  • 8.6.2 UAE
  • 8.6.3 SAUDI ARABIA
  • 8.6.4 SOUTH AFRICA
  • 8.6.5 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPANY MARKET RANKING ANALYSIS,
• 9.3 COMPANY REGIONAL FOOTPRINT
• 9.4 COMPANY INDUSTRY FOOTPRINT
• 9.5 ACE MATRIX
  • 9.5.1 ACTIVE
  • 9.5.2 CUTTING EDGE
  • 9.5.3 EMERGING
  • 9.5.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 PFIZER
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 COMPANY INSIGHTS
  • 10.1.3 SEGMENT BREAKDOWN
  • 10.1.4 PRODUCT BENCHMARKING
  • 10.1.5 KEY DEVELOPMENTS
  • 10.1.6 WINNING IMPERATIVES
  • 10.1.7 CURRENT FOCUS & STRATEGIES
  • 10.1.8 THREAT FROM COMPETITION
  • 10.1.9 SWOT ANALYSIS
• 10.2 INNOVATIVE MED CONCEPTS
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 COMPANY INSIGHTS
  • 10.2.3 SEGMENT BREAKDOWN
  • 10.2.4 PRODUCT BENCHMARKING
  • 10.2.5 KEY DEVELOPMENTS
  • 10.2.6 WINNING IMPERATIVES
  • 10.2.7 CURRENT FOCUS & STRATEGIES
  • 10.2.8 THREAT FROM COMPETITION
  • 10.2.9 SWOT ANALYSIS
• 10.3 NOVARTIS AG
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 COMPANY INSIGHTS
  • 10.3.3 SEGMENT BREAKDOWN
  • 10.3.4 PRODUCT BENCHMARKING
  • 10.3.5 KEY DEVELOPMENTS
  • 10.3.6 WINNING IMPERATIVES
  • 10.3.7 CURRENT FOCUS & STRATEGIES
  • 10.3.8 THREAT FROM COMPETITION
  • 10.3.9 SWOT ANALYSIS
• 10.4 ELI LILLY & COMPANY
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 COMPANY INSIGHTS
  • 10.4.3 SEGMENT BREAKDOWN
  • 10.4.4 PRODUCT BENCHMARKING
  • 10.4.5 KEY DEVELOPMENTS
  • 10.4.6 WINNING IMPERATIVES
  • 10.4.7 CURRENT FOCUS & STRATEGIES
  • 10.4.8 THREAT FROM COMPETITION
  • 10.4.9 SWOT ANALYSIS
• 10.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 COMPANY INSIGHTS
  • 10.5.3 SEGMENT BREAKDOWN
  • 10.5.4 PRODUCT BENCHMARKING
  • 10.5.5 KEY DEVELOPMENTS
  • 10.5.6 WINNING IMPERATIVES
  • 10.5.7 CURRENT FOCUS & STRATEGIES
  • 10.5.8 THREAT FROM COMPETITION
  • 10.5.9 SWOT ANALYSIS
• 10.6 INTEC PHARMA LTD.
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 COMPANY INSIGHTS
  • 10.6.3 SEGMENT BREAKDOWN
  • 10.6.4 PRODUCT BENCHMARKING
  • 10.6.5 KEY DEVELOPMENTS
  • 10.6.6 WINNING IMPERATIVES
  • 10.6.7 CURRENT FOCUS & STRATEGIES
  • 10.6.8 THREAT FROM COMPETITION
  • 10.6.9 SWOT ANALYSIS
• 10.7 ABBVIE
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 COMPANY INSIGHTS
  • 10.7.3 SEGMENT BREAKDOWN
  • 10.7.4 PRODUCT BENCHMARKING
  • 10.7.5 KEY DEVELOPMENTS
  • 10.7.6 WINNING IMPERATIVES
  • 10.7.7 CURRENT FOCUS & STRATEGIES
  • 10.7.8 THREAT FROM COMPETITION
  • 10.7.9 SWOT ANALYSIS
• 10.8 FSD PHARMA
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 COMPANY INSIGHTS
  • 10.8.3 SEGMENT BREAKDOWN
  • 10.8.4 PRODUCT BENCHMARKING
  • 10.8.5 KEY DEVELOPMENTS
  • 10.8.6 WINNING IMPERATIVES
  • 10.8.7 CURRENT FOCUS & STRATEGIES
  • 10.8.8 THREAT FROM COMPETITION
  • 10.8.9 SWOT ANALYSIS
• 10.9 MERCK & CO.
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 COMPANY INSIGHTS
  • 10.9.3 SEGMENT BREAKDOWN
  • 10.9.4 PRODUCT BENCHMARKING
  • 10.9.5 KEY DEVELOPMENTS
  • 10.9.6 WINNING IMPERATIVES
  • 10.9.7 CURRENT FOCUS & STRATEGIES
  • 10.9.8 THREAT FROM COMPETITION
  • 10.9.9 SWOT ANALYSIS
• 10.10 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 COMPANY INSIGHTS
  • 10.10.3 SEGMENT BREAKDOWN
  • 10.10.4 PRODUCT BENCHMARKING
  • 10.10.5 KEY DEVELOPMENTS
  • 10.10.6 WINNING IMPERATIVES
  • 10.10.7 CURRENT FOCUS & STRATEGIES
  • 10.10.8 THREAT FROM COMPETITION
  • 10.10.9 SWOT ANALYSIS

관련자료